TruScreen Eyes 65% Sales Surge in FY26 with Emerging Market Push

• FY25 sales declined to NZ$1.7m due to program delays
• FY26 sales projected to exceed NZ$2.8m, a 65% increase
• Expansion focused on China’s six provinces and emerging markets
• New public screening programs in Vietnam, Zimbabwe, and others
• Strategic partnership with Dalton BioScience to broaden product portfolio

TruScreen’s FY25 Performance and Challenges

TruScreen Group Ltd, a life sciences company dual-listed on the ASX and NZX, reported FY25 sales of NZ$1.7 million, down from NZ$2.1 million in FY24. This decline was primarily due to delays in key emerging market programs, including Zimbabwe, Vietnam, Indonesia, and Uzbekistan. These setbacks postponed expected revenue streams, but the company remains optimistic that these will materialize in FY26.

Strategic Focus on Emerging Markets

TruScreen’s core strategy targets emerging economies such as China, India, Indonesia, Mexico, Uzbekistan, Vietnam, and Zimbabwe, regions with limited or no large-scale cervical cancer screening infrastructure. This approach leverages a significant market gap, allowing TruScreen to introduce its AI-enabled, capital-light screening technology without the need for extensive lab infrastructure. The company’s recurring revenue model, driven by disposable Single Use Sensors for each screening, supports sustainable growth.

Growth Drivers and Market Expansion

Looking ahead, TruScreen projects FY26 sales to exceed NZ$2.8 million, a substantial 65% increase. Key growth will come from resumed public health programs in Zimbabwe and Vietnam, where a 5-year screening initiative targeting 260,000 women in Ho Chi Minh City has recently been formalized. Additionally, new commercial activities have commenced in Indonesia and India, broadening TruScreen’s footprint in populous markets with urgent screening needs.

China remains the linchpin of TruScreen’s expansion, with its distributor Beijing Siweixiangtai Technology Co Ltd targeting six provinces that collectively represent nearly 500 million people and an addressable market of 124 million women. The company’s dual-device strategy, manufacturing locally in China and Australia, mitigates tariff risks and facilitates preferential market access. Public health insurance reimbursement in Beijing and pending approval in Shanghai are expected to accelerate sales growth further.

Strategic Partnerships and Validation

TruScreen’s recent Memorandum of Understanding with Dalton BioScience enhances its global distribution capabilities, excluding North America, and introduces complementary HPV DNA testing products. This partnership aligns with TruScreen’s ambition to expand its AI-enabled cervical cancer screening portfolio and capitalize on global health trends.

Independent studies and endorsements bolster TruScreen’s credibility. The World Health Organization and UNITAID have recognized the company’s technology, and peer-reviewed research from institutions in China and Saudi Arabia confirms its screening accuracy surpasses traditional methods like Pap smears in certain cases.

Looking Forward

TruScreen’s FY26 outlook is ambitious but grounded in tangible progress across multiple emerging markets. The company’s focus on AI-driven innovation, strategic partnerships, and expanding public health programs positions it well to capture significant market share in regions with critical unmet needs for cervical cancer screening.

Bottom Line?

TruScreen’s FY26 growth hinges on execution in emerging markets and regulatory momentum, setting the stage for a pivotal year.

Questions in the middle?

• Will TruScreen’s delayed programs in Zimbabwe and Vietnam deliver as projected in FY26?
• How will regulatory and reimbursement approvals in China’s provinces impact sales momentum?
• Can TruScreen’s partnership with Dalton BioScience accelerate adoption beyond current markets?